Robert McBride
San Francisco, California, United States
5K followers
500+ connections
5K followers
500+ connections
About
Operations leader and YC-backed founder with two decades building and scaling ventures at…
Activity
5K followers
-
Robert McBride shared thisRobert McBride shared thisSee my interview with Josh Bloom of the American Council on Science and Health. https://lnkd.in/eJQcf7PtHow Bad is Antibiotic Resistance Today? An Interview with Dr. David Shlaes.How Bad is Antibiotic Resistance Today? An Interview with Dr. David Shlaes.
-
Robert McBride shared thisRobert McBride shared thisWe are pleased to share a barrier-free, open-source and expandable Klebsiella phage and strain collection for your research: KlebPhaCol (Klebsiella Phage Collection)! Our aim is to set up an accessible and representative collection of phages and strains to move research forward as we face the increasingly dangerous threat of antimicrobial resistance. We created KlebPhaCol with the vision to create an open and collaborative research space to make data accessible and readily available. KlebPhaCol can be requested at klebphacol.org Request, use and share! You can also contribute by adding your Klebsiella-targeting phages and strains to KlebPhaCol. A collection by scientists, for scientists. To learn more, visit klebphacol.org Follow us on twitter @klebphacol
-
Robert McBride shared thisRobert McBride shared this“Antimicrobial resistance (AMR) can negatively affect cancer patients by reducing anticancer treatment efficacy, inducing chronic infection, and increasing mortality risk.” There are currently 1300 cancer treatments in clinical trials and 27 antibiotics. We’re building a palace of innovation on a shaky fault line. #amr #antimicrobialresistance #antibioticresistance #moonshot World Anti-Microbial Resistance Congress, AMR Action FundThe Impact of Antimicrobial Resistance on Cancer PatientsThe Impact of Antimicrobial Resistance on Cancer Patients
-
Robert McBride shared thisRobert McBride shared thisI WAS FEATURED ON FORBES🤯! Thank you Andrew Wight of Forbes sharing my story and aspirations as a biomedical researcher and for an article that gives deserved attention to my country and continent where biotech innovation has the potential to transform healthcare. Here is the link to the full article: https://lnkd.in/ejH9GyZq Thank you to everyone who has been a part of my journey thus far👏. I am inviting you to help me fulfill my desire to revolutionise Africa’s healthcare system by contributing to my university tuition through my fundraising campaign. Here's my GoFundMe campaign: https://gofund.me/63d8fece Jennifer Jones, Ph.D. Janet Nale Jessica Sacher Tunji Akintokun MBE CCMI Jennifer Zabasajja Trevor Ncube Charlene Chabata, PhD Eric Musonza Minmin Yen, Ph.D., MPH (she/her) Annie Pasternak Tibor Mozes Rajiv Kapoor Tonya Taylor Tobi Nagel Jeff Reich Carolina Barsa Jonathan Scheiman, PhD Dawn Sibanda. MD, PharmD, MPH. Dr. Sangu Delle Margaret Nyamumbo Margaret Black Nicole Small Karen Akinsanya, PhD Vincent Fischetti Jean-Laurent Casanova Forbes Ignite Mhairi McCann Nicole C. Cacal Brian Woodfall Randall Lane Baylor University Tererai Trent Michael Pollastri Sina Ghaemmaghami Fabiana Feitosa-Suntheimer Peter Hotez MD PhD Deepali Ravel #biomedicine #biotech #medicine #bacteriophage #phagetherapy #phages #crispr #tuberculosis #malaria #cholera #hivaids #aids #malaria #tropicaldiseases #disease #virus #drugdiscovery #zimbabwe #subsaharanafrica #africa #biology #premed #globalhealth #studyinusa #forbesfeature #forbesinterview #forbesrecognition #forbesscience #artsandsciences #interview #gofundme #fundraising
-
Robert McBride shared thisRobert McBride shared thisSome images from last week's ESCMID - European Society of Clinical Microbiology and Infectious Diseases (ESGNTA - ESCMID Study Group for Non-Traditional Antibacterial Therapy) Postgraduate Technical Workshop on "Personalized phage therapy: from the lab to the patient", at the Queen Astrid military hospital in Brussels (Royal Military Academy, Belgium , Royal Higher Institute for Defence, Defensie). #phage #phagetherapy
-
Robert McBride shared thisRobert McBride shared thisThere's a wonderful guest essay in today's New York Times about cystic fibrosis and how an entire generation of people who had been condemned to short lives now needs to learn how to live full lives. It's a hard question to ask, but it's one people with CF on Trikafta have been asking without satisfying answers for a few years. After six months of being on the drug I was overwhelmed with needing to think about the rest of my life. I was fortunate that I was in my late 20s when Trikafta hit. I pulled through about 5 years of severe disruption to my career because of my health. I was lucky that it was only 5, but it still frustrates me today that those 5 years should have been my most formative years in my career. It’s why I then went to business school to catch up. In a lot of ways it still feels like I’m catching up and playing from behind. For others who were in their 30s/40s with CF when Trikafta hit… the disruption has been magnified. We’ve found that a lot of people were in jobs that were accommodating in the short term rather than geared towards career growth, and those are hard choices to undo later in life... I know a lot of my friends with cystic fibrosis feel very seen by this essay.Opinion | What It’s Like to Learn You’re Going to Live Longer Than You ExpectedOpinion | What It’s Like to Learn You’re Going to Live Longer Than You Expected
-
Robert McBride shared thisRobert McBride shared thisAMR (antibiotic and antifungal resistance) does NOT discriminate. No one is safe. Please read this New York Times piece by Andrew Jacobs to learn about an interesting approach to this urgent global health crisis. https://lnkd.in/e6ts3wuz #kevinoutterson; #jenniferburke; #roberthorne #kenthorpe, #PFID, #IDSA, #awg, #CSIS, #amr #phage, #health, #cff, #daveelinCan a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics? (Published 2022)Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics? (Published 2022)
-
Robert McBride shared thisNew #phage engineering tools are essential as we develop effective #phageTherapy techniques and more. In our new Nature Microbiology paper with our fantastic collaborators from Joe Bondy-Denomy's lab, we develop #CRISPR-based tools to engineer jumbo phages. These tools may make it possible to study phages that are otherwise difficult to work with and open these phages to a wide variety of applications. Many thanks to everyone who made this incredible work possible including Jingwen Guan, Agnès Oromí Bosch, Senén D. Mendoza, Shweta Karambelkar, and Joel Berry, PhD! https://lnkd.in/db-3z6cJ #biotech #research
-
Robert McBride shared this#teamworkmakesthedreamwork! Dare devils on the Felix team recently tested their dare-devilishness with a sky diving outing at Skydive Golden Gate. If you'd like to join our intrepid team of #phage wranglers, check out our open positions here: https://lnkd.in/gTJZeEv6 #Teamwork #Biotech #Careers #Science #ScienceCareers #BiotechJobs
-
Robert McBride liked thisRobert McBride liked thisI'm excited to share that I've joined the Phillips 66 Commercial & Trading organization as Vice President, Global Market Research & Strategy. I'm grateful for the opportunity to help strengthen Phillips 66's market research capabilities, maximize the value of its world-class asset base, and support the expansion of its value chain and trading activities across global markets. Thank you to the colleagues, mentors and teams who have supported me along the way. I'm proud to be part of the next chapter of Phillips 66's journey and look forward to what lies ahead. #Phillips66 #EnergyTrading #EnergyMarkets
-
Robert McBride liked thisRobert McBride liked thisI've looked at a lot of YC batches. The bio and health lineup in P26 is STACKED. https://lnkd.in/gQKxpe9t Adialante - Compact, mobile whole-body MRI to make cancer screening accessible at hundreds per scan FinalDose - A programmable drug that reads DNA inside the cell and destroys it if it's diseased, starting with previously undruggable cancer targets Voquill (YC P26) - An AI coworker for pathologists that learns your reporting style and produces sign-out ready reports in real time Clara - An AI primary care doctor with a licensed clinician reviewing every medical decision Lumius (YC P26) - Affordable, real-time 3D ultrasound, starting with vascular access
-
Robert McBride liked thisRobert McBride liked this#BIO2026- that’s a wrap! Great to see old friends, make new ones, and share our team’s great work on multiple GPCR antibody agonist programs with so many parties. Something in the air besides beautiful San Diego ocean breezes…. I’m calling it wafts of biotech optimism. I hope you all have a great summer and second half of the year. Until next time, BIO and SD!
-
Robert McBride liked thisRobert McBride liked thisAssort Health is now a unicorn! $1.2B to be exact, in just 3 years. Huge congrats to Jeffery L. and Jon Wang and the whole Assort team. They're solving the frustrating operational problems in healthcare, making it easier for doctors and their patients to communicate. I and the Pioneer Fund team are proud to have backed them since the beginning. https://lnkd.in/gr9vN7pvAssort Health Raises $120M Series C at $1.2B ValuationAssort Health Raises $120M Series C at $1.2B Valuation
-
Robert McBride liked thisRobert McBride liked thisDespite years of promising research on the importance of microbiomes in human and environmental health, very few microbiome companies have successfully scaled. At the JBIMS Microbiome Innovation Forum, I had the honor of hosting a panel discussion with experts across microbiome research, funding, company development, and artificial intelligence to ask: What is holding back microbiome technology and how might AI help us overcome these limitations? My biggest takeaway: Despite challenges in commercialization, the promise of microbiome technology is not diminished. AI tools are proving helpful for designing microbial consortia that are effective outside of the lab. And with their aid, a new wave of exciting microbial technologies is on the horizon. Thank you to our awesome panelists! - Jessica Green (Advanced Research Projects Agency for Health (ARPA-H)) - Adam Arkin (Berkeley Lab, University of California, Berkeley) - Jenny Yang (Outpost Bio) - Cheri Ackerman Araromi (Concerto Biosciences) - Srilekha Bhattiprolu (Juniper) We’re putting together a more detailed post-event synthesis describing technical and economic bottlenecks in microbiome technology development and how people are using AI to aid in microbiome research translation. Shoot me a message or comment to get on the mailing list! Thanks to Britt Koskella, Eoin Brodie, Jonelle Tamara Basso, and the Joint Berkeley Initiative for Microbiome Sciences community for making it happen!
-
Robert McBride liked thisRobert McBride liked thisThrilled to share that Engage Bio has been acquired by Eli Lilly and Company for up to $202 million. Will and the team are exactly the kind of founders we aim to back at Pioneer Fund: exceptional scientists solving a problem the field had largely written off as too hard. A small team can do big science. Proud to have supported them early and grateful to have been part of this journey. Congrats to the whole Engage Bio team! https://lnkd.in/gP3H4b82Eli Lilly Acquires Engage Bio for Up to $202 MillionEli Lilly Acquires Engage Bio for Up to $202 Million
-
Robert McBride liked thisRobert McBride liked thisI am extremely proud to announce that Laguna is officially a clinical-stage company following FDA clearance of our IND to evaluate LGNA-100, our lead asset from the QUAIL platform in AML with a primary focus in pediatric leukemia. AML has been one of the most formidable and devastating diseases, and pediatric patients experience an especially high unmet need. While the introduction of FLT-3 inhibitors have been impactful for specific patients, the majority are left without options after venetoclax relapse. While immunotherapies have been transformative for other hematological malignancies, they have so far failed due to severe toxicities from on-tumor/off-target effects in AML. Researchers like Dr. Alice Bertaina at Stanford have made breakthrough discoveries showing that properly activated γδ T cells kill AML blasts, improving overall survival and decreasing the risk of GvHD and opportunistic infections post-transplant. We have worked closely with the Bertaina lab to show that QUAIL uniquely activates and significantly and durably expands endogenous γδ T cells within patients. Reaching this milestone required tremendous dedication from our team and our collaborators. Especially Russell, Barbara, Ly, Michele DeVries, Dr. Alice Bertaina, Dr. Orly Klein, Chris, Edward, Dr. Portnoy, Raf, Mariya, Preethi, Jim, and others. The QUAIL platform represents a profound and necessary paradigm shift, recognizing that the most elegant, powerful, and controllable immune activators have already been designed by millions of years of evolution. Success would mean that AML patients would benefit from the immunotherapy revolution. #AML #PediatricCancer #IND #QUAIL #Biotech
-
Robert McBride liked thisWe’re partnering with Eli Lilly and Company to develop AI-designed recombinases for genetic medicine. Inserting long stretches of DNA, sometimes entire genes, at precise locations in the genome is one of the hardest unsolved problems in gene editing. Nature has evolved recombinases with remarkable diversity and specificity, but designing them for therapeutic targets has remained largely out of reach until now. By training AI models on the world's largest database of natural recombinase sequences, we can learn the rules of protein-DNA recognition and use them to design proteins that precisely insert DNA where it is needed in the human genome. Congrats to the whole Profluent team on this milestone.Robert McBride liked thisToday we announced a landmark partnership with Eli Lilly and Company to use our AI models to design recombinases for genetic medicine—a collaboration valued at up to $2.25 billion before royalties. The goal: use Profluent's AI models to design recombinase editors capable of inserting long stretches of DNA at precise locations in the genome. Many genetic diseases involve hundreds of different mutations across patients–no single edit can address them all. Inserting a complete functional gene with a recombinase editor opens the potential to address diseases with high mutational heterogeneity using a single therapeutic, rather than developing a separate editor for every variant. This has been a long sought goal in the gene editing field, but current tools can't reliably make insertions at that scale. Naturally occurring recombinases could but are limited in where they can act and traditional metagenomic discovery and protein engineering approaches can't precisely control their targeting. Our frontier AI models design custom recombinases from scratch, programmable to target virtually any location in the genome. We're collaborating with Lilly to turn that capability into medicines. Read the press release for more: https://lnkd.in/e5_NQUw8
-
Robert McBride liked thisRobert McBride liked thisEvery deep tech founder faces what I call the Narrowness Dilemma: go too broad and visionary and you sound naive. Go too specific and technical and you lose the room. At Bunsen, we work with companies to tackle this problem every single day, finding the story that's bold enough to inspire but grounded enough to earn trust. On Friday, May 7 at 12p ET, I'm joining a panel at SynBioBeta to dig into how biotech founders can get it right. We've got a great mix of perspectives, including practitioners (like Erin Kim, JD, Kevin Costa) and founders (like Stephanie Wisner, Jodi Barrientos) who've been on both sides of the table. Would love to see you there. CC John Cumbers
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
Publications
Other similar profiles
Explore more posts
-
Joe Fernandez
Active Motif Licenses Caltech’s ChIP-DIP™ Technology for Massively Multiplexed Genome-Wide DNA–Protein Interaction Mapping I’m very excited to share that Active Motif has officially licensed the intellectual property from Mitch Guttman’s lab at Caltech for ChIP-DIP™ — a next-generation chromatin profiling technology that allows us to measure 10 to 100 DNA–protein interactions at the same time, genome-wide, in a single experiment. This moves us beyond the traditional one-factor-at-a-time view of epigenetics and finally lets us study gene regulation as an integrated system. In our own labs, working closely with Mitch’s team, we have already successfully performed >14 simultaneous DNA–protein binding events, and we’re excited about how quickly this technology is progressing. What ChIP-DIP now makes possible: • Mapping of multiple chromatin states across the genome in a singe experiment • Viewing regulatory networks instead of isolated binding events • Identification of simultaneous of multi-factor regulatory signatures linked to cancer, inflammation, and development • Discovery of combinatorial epigenetic patterns that single-target assays miss • Studying chromatin dynamics in response to stimuli and drug treatments • Building true systems-level models of gene regulation • Creating rich regulatory datasets for AI, predictive genomics, and biomarker discovery Techniques we all rely on — ChIP-seq, CUT&RUN, and CUT&Tag — will always remain important tools. But they simply can’t generate the kind of high-dimensional, multiplexed regulatory data that ChIP-DIP now enables. We believe this scale of data is exactly what the field needs to take the next real leap in understanding how the genome is regulated in both health and disease. A heartfelt thank you to the Guttman Lab at Caltech for their innovation and partnership, and to the incredible teams at Active Motif in Licensing, Marketing, and R&D who worked tirelessly to bring this together. Our focus now is on making ChIP-DIP robust, scalable, and easy to use, including the development of ready-to-use multiplex panels. I’d truly love your input—if you could design your ideal multiplex panel, which targets would you want included?
5 Comments -
Centre of Bioinformatics Research and Technology (CBIRT)
A recent study from UC San Diego introduces #PanMAN (Pangenome Mutation-Annotated Network), a lossless and highly compressed pangenome format designed to scale to millions of genomes while capturing mutational and evolutionary history. PanMAN achieved up to 1,391× compression and enabled construction of a SARS-CoV-2 pangenome from 8 million sequences in just 366 MB, supporting faster, more scalable pangenomic analysis. With tools like #panmanUtils, it offers a promising foundation for large-scale genomics and pathogen surveillance.🧬 Quick Read: https://lnkd.in/gknHGTZy #Bioinformatics #Genomics #Pangenomics #Genomics #SARSCoV2 #GenomeAnalysis #DataCompression #GenomicDataScience #ScienceNews
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Robert McBride in United States
474 others named Robert McBride in United States are on LinkedIn
See others named Robert McBride